Nov 02, 2023
|
Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference
|
|
Oct 26, 2023
|
Vertex to Present at Upcoming Investor Conferences
|
|
Oct 10, 2023
|
Vertex to Announce Third Quarter 2023 Financial Results on November 6
|
|
Oct 05, 2023
|
Vertex Appoints Michel Lagarde to its Board of Directors
|
|
Oct 03, 2023
|
Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting
|
|
Sep 15, 2023
|
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
|
|
Sep 14, 2023
|
Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
|
|
Aug 30, 2023
|
Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13
|
|
Aug 29, 2023
|
Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations
|
|
Aug 03, 2023
|
Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine
|
|
Aug 01, 2023
|
Vertex Reports Second Quarter 2023 Financial Results
|
|
Jul 05, 2023
|
European Commission Approves ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old
|
|
Jun 30, 2023
|
Vertex to Announce Second Quarter 2023 Financial Results on August 1
|
|
Jun 26, 2023
|
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
|
|
Jun 23, 2023
|
Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
|
|
Jun 09, 2023
|
Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
|
|
Jun 09, 2023
|
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
|
|
Jun 08, 2023
|
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
|
|
May 30, 2023
|
Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
|
|
May 03, 2023
|
Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
|
|